SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-105964
Filing Date
2023-10-02
Accepted
2023-10-02 17:06:34
Documents
14
Period of Report
2023-09-28
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2322367d5_8k.htm   iXBRL 8-K 34745
2 EXHIBIT 16.1 tm2322367d5_ex16-1.htm EX-16.1 2265
  Complete submission text file 0001104659-23-105964.txt   257365

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeon-20230928.xsd EX-101.SCH 3369
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aeon-20230928_def.xml EX-101.DEF 26589
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeon-20230928_lab.xml EX-101.LAB 36481
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeon-20230928_pre.xml EX-101.PRE 25213
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2322367d5_8k_htm.xml XML 5006
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 231300563
SIC: 2834 Pharmaceutical Preparations